BUSINESS

Meiji to Set Up JV with Canadian Firm to Develop Novel β-lactamase Inhibitor

January 9, 2019
Meiji Seika Pharma said on January 8 that it has reached a basic agreement with Canada's Fedora Pharmaceuticals to establish a joint venture to develop and commercialize the β-lactamase inhibitor nacubactam (development code: OP0595/FPI-1459/RO7079901). Meiji and Fedora licensed the rights…

To read the full story

BUSINESS

By Reiji Anasako

Big pharma companies are ramping up the number of female bosses in Japan, with the percentage of women in managerial posts reaching 20% or more for seven out of 10 firms that disclosed their most recent data to Jiho by…

By Yoshinori Sagehashi

As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…

By Takashi Ebisawa and Tatsuya Otsuka

Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…

By Yoshinori Sagehashi

Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…

By Takashi Ebisawa

Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…